Y Intercept Hong Kong Ltd Decreases Position in Guardant Health, Inc. (NASDAQ:GH)

Y Intercept Hong Kong Ltd lowered its stake in Guardant Health, Inc. (NASDAQ:GH) by 76.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,936 shares of the company’s stock after selling 38,937 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Guardant Health were worth $274,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Guardant Health by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after acquiring an additional 796 shares during the last quarter. JNBA Financial Advisors acquired a new stake in Guardant Health in the third quarter worth $26,000. Wexford Capital LP increased its position in Guardant Health by 13.0% in the third quarter. Wexford Capital LP now owns 10,081 shares of the company’s stock worth $231,000 after buying an additional 1,158 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Guardant Health in the third quarter worth about $34,000. Finally, Quarry LP acquired a new stake in Guardant Health in the second quarter worth about $44,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Musa Tariq sold 2,320 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,316 shares of company stock valued at $171,380 over the last ninety days. 5.50% of the stock is owned by company insiders.

Guardant Health Stock Down 7.1 %

GH stock opened at $32.36 on Thursday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $38.53. The business’s 50 day moving average price is $28.48 and its two-hundred day moving average price is $28.27. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -7.63 and a beta of 1.26.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same period in the prior year, the business posted ($0.73) earnings per share. Guardant Health’s revenue for the quarter was up 33.9% compared to the same quarter last year. As a group, analysts forecast that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GH. JPMorgan Chase & Co. lifted their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. UBS Group upped their price target on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Sanford C. Bernstein cut their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. The Goldman Sachs Group upped their target price on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Leerink Partners decreased their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Fifteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $40.60.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.